Olema Pharmaceuticals, Inc.

NASDAQ:OLMA

Biotechnology

Healthcare
$7.06 -2.70%

-$0.26 today

Market cap
$618.50M
Beta
2.00
P/E (TTM)
-5.1
EPS (TTM)
-$1.80
52W Low $4.02High $36.26

Volume 1.18M

Average 1.27M

OLMA Sales of Investments

Cash received from selling or redeeming investments.

Olema Pharmaceuticals, Inc.NASDAQ: OLMA

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments declines year over year

Q1 FY2026 sales of investments of $74.47M fell 23.8% year over year, behind the -6.3% change in trailing-twelve-month sales of investments. Sequentially, it fell 18.3% from the prior quarter. Over 3 fiscal years it compounded at +4.1% a year.

Context

  • Sales of investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -23.8% toward the trailing-twelve-month pace of -6.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$74.47M-18.3% QoQ
Last fiscal yearDec 2025
$344.96M+14.4% YoY
LTMMar 2026
$321.66M-6.3% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.8%——
1 year+14.4%——
3-year CAGR+4.1%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
344.96M USD
Year-over-year change
+14.4%
4-year CAGR
+12.8%

Sales of Investments vs competitors

How OLMA compares with its peers on the latest reported figures

  • OLMA's LTM Mar 2026 sales of investments of $321.66M is the largest of the 2 companies compared; the peer median is $85.26M.
  • Its year-over-year change of -6.3% is the lowest of 2, against a peer median of +33.1%.
  • Over three fiscal years its annual growth of +4.1% compares with a peer median of +56.1%.
OLMA Competitors Peer median
Sales of Investments for OLMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$321.66M -6.3%+4.1%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$85.26M +33.1%+56.1%37.5%
Peer median (excluding OLMA) $85.26M+33.1%+56.1%37.5%

Competitors are the stored peer set for OLMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.1M)(104.79M)(96.66M)(129.47M)(162.45M)
Depreciation & Amortization1.66M1.66M377K393K490K
Deferred Income Tax00000
Stock-Based Compensation0017.26M22.58M17.59M
Change in Working Capital2.83M3.02M(589K)9.16M2.78M
Accounts Receivables00000
Inventory00000
Accounts Payables(683K)351K2.32M2.51M4.6M
Other Working Capital3.51M2.67M(2.91M)6.65M(1.82M)
Other Non-Cash Items15.91M18.04M(4.12M)(7.02M)(5.12M)
Operating Cash Flow(50.69M)(82.07M)(83.73M)(104.35M)(146.72M)
Capital Expenditures(1.58M)(363K)0(159K)0
Acquisitions (Net)00000
Purchases of Investments(486.97M)(213.66M)(255.63M)(394.96M)(500.72M)
Sales of Investments213.1M305.5M250.76M301.59M344.96M
Other Investing Activities0014K00
Investing Cash Flow(275.44M)91.48M(4.85M)(93.53M)(155.76M)
Debt Repayment00003M
Common Stock Issued1.39M476K129.74M266.29M208.3M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities003.68M2.53M0
Financing Cash Flow1.39M476K133.42M268.82M211.3M
Effect of Forex Changes00000
Net Change in Cash(324.74M)9.89M44.84M70.94M(91.18M)
Free Cash Flow(52.27M)(82.43M)(83.73M)(104.51M)(146.72M)

Olema Pharmaceuticals, Inc.

NASDAQ:OLMA

Intrinsic Alpha fair value

Locked

Current Price

$7.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.